OSA treatment improves symptoms and quality of life, but evidence for cardiovascular event reduction remains heterogeneous and strongly influenced by patient selection and treatment adherence.
This review highlights that while obstructive sleep apnea treatments improve symptoms, their impact on reducing cardiovascular events is heterogeneous and highly dependent on patient selection and adherence.
Obstructive sleep apnea (OSA) is a sleep-disordered breathing condition characterized by recurrent upper-airway obstruction, leading to intermittent hypoxemia, sleep fragmentation, and sympathetic activation. OSA is highly prevalent in patients with cardiovascular diseases and is strongly associated with hypertension, atrial fibrillation, coronary artery disease, heart failure, and adverse prognosis. This review summarizes current evidence on the pathophysiology of OSA, its cardiovascular consequences, and available diagnostic and therapeutic strategies, with particular attention to clinical implications in cardiology practice. We discuss established treatments such as lifestyle interventions, continuous positive airway pressure, mandibular advancement devices, and selected surgical options, as well as emerging therapies, including pharmacological approaches targeting weight loss and ventilatory control. While OSA treatment improves symptoms and quality of life, evidence for cardiovascular event reduction remains heterogeneous and appears strongly influenced by patient selection and treatment adherence. Identifying patients most likely to benefit from targeted OSA management remains a key challenge.
Castiglione et al. (Thu,) conducted a review in Obstructive sleep apnea (OSA). OSA treatment improves symptoms and quality of life, but evidence for cardiovascular event reduction remains heterogeneous and strongly influenced by patient selection and treatment adherence.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: